Online citations, reference lists, and bibliographies.
← Back to Search

In Vitro And In Vivo Evaluation Of Tumor Targeting Styrene‐maleic Acid Copolymer‐pirarubicin Micelles: Survival Improvement And Inhibition Of Liver Metastases

J. Daruwalla, M. Nikfarjam, K. Greish, C. Malcontenti-Wilson, V. Muralidharan, C. Christophi, H. Maeda
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Pirarubicin is a derivative of doxorubicin with improved intracellular uptake and reduced cardiotoxicity. We have prepared a micellar formulation of pirarubicin using styrene‐maleic acid copolymer (SMA) of mean molecular weight of 1.2 kDa, which exhibits a mean diameter of 248 nm in solution. Being a macromolecule, SMA‐pirarubicin micelles exhibit excellent tumor targeting capacity due to the enhanced permeability and retention (EPR) effect. Here we report the antitumor activity of SMA‐pirarubicin micelles on human colon and breast cancer cell lines in vitro, and a murine liver metastasis model in vivo. Metastatic tumor microvasculature, necrosis, apoptosis, proliferation, and survival were also investigated using immunohistochemistry for Ki‐67, active caspase‐3, and CD34, respectively. Drug cytotoxicity in vitro was assessed using MTT (3‐[4,5‐dimethyl‐2‐thiazolyl]‐2, 5‐diphenyl‐2H‐tetrazolium bromide) assay. In vivo, SMA‐pirarubicin was administered at 100, 150, or 200 mg/kg (pirarubicin equivalent). Tumor microvasculature was also assessed using scanning electron microscopy. Styrene‐maleic acid copolymer (SMA)‐pirarubicin micelles were toxic against human colorectal and breast cancer cells in vitro. IC50 was at or below 1 μM, free pirarubicin equivalent. In vivo, SMA‐pirarubicin at 100 mg/kg reduced tumor volume by 80% and achieved a survival rate of 93% at 40 days after tumor inoculation. Styrene‐maleic acid copolymer (SMA)‐pirarubicin micelles demonstrated potent antitumor activity in this liver metastases model, contributing to prolonged survival. Histological examination of tumor nodules showed significant reduction and proliferation of tumor cells (>90%). The present results suggest that investigation of the effect of multiple dosing at later time points to further improve survival is warranted. (Cancer Sci 2010)
This paper references
4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
T. Tsuruo (1982)
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
J. N. Munck (1993)
Microvascular architecture of experimental colon tumors in the rat.
S. Skinner (1990)
Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
S. Hirano (1994)
10.1021/BC040297G
Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
K. Greish (2005)
10.1016/S0002-9440(10)64920-6
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.
S. Morikawa (2002)
10.1159/000216753
Phase II study of pirarubicin in metastatic breast cancer.
U. Kleeberg (1990)
Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.
K. Iwai (1984)
10.1002/1097-0142(19850815)56:4<751::AID-CNCR2820560409>3.0.CO;2-Y
Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium
S. Maki (1985)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F
Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium
T. Konno (1984)
10.1016/S0002-9440(10)65006-7
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
10.1016/J.JCONREL.2004.03.027
SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours.
K. Greish (2004)
10.1111/J.1349-7006.1994.TB02362.X
Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor
H. Maeda (1994)
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
D. Blakey (2002)
10.1080/10611860701499839
Evaluation of the effect of SMA–pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice
J. Daruwalla (2007)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1097/00000421-199012001-00002
Intra‐Arterial Hepatic Chemotherapy with Pirarubicin: Preclinical and Clinical Studies
P. Rougier (1990)
10.1016/S0168-3659(01)00309-1
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
H. Maeda (2001)
Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
C. Malcontenti-Wilson (2001)
10.1016/j.ejpb.2008.11.010
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
H. Maeda (2009)
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.
J. Wu (1998)
10.1126/SCIENCE.6823562
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
D. Senger (1983)
10.1002/ijc.10610
Persistent oxidative stress in colorectal carcinoma patients
D. Gackowski (2002)
10.1006/JSRE.2001.6299
Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol.
D. Kuruppu (2002)
Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer.
H. Maeda (1988)
10.1111/j.1349-7006.2001.tb01114.x
Enhanced Vascular Permeability in Solid Tumor Involving Peroxynitrite and Matrix Metalloproteinases
J. Wu (2001)
10.1200/JCO.1990.8.4.705
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
F. Lévi (1990)
Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
R. Zhou (2002)
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.
H. Dvorak (1988)
10.1016/0277-5379(83)90028-7
Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.
T. Konno (1983)
10.1152/AJPCELL.00353.2002
A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis.
K. J. Kelly (2003)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1111/j.1349-7006.1999.tb00814.x
Membrane Transport and Antitumor Activity of Pirarubicin, and Comparison with Those of Doxorubicin
T. Sugiyama (1999)
Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function.
J. Grunstein (1999)
10.1111/j.1440-1746.1996.tb00006.x
Characterization of an animal model of hepatic metastasis
D. Kuruppu (1996)
10.1038/sj.bjc.6601490
ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
M. McCarty (2004)
ZD 6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
KJ Kelly (2004)
10.1002/JSO.20289
Effect of thalidomide on colorectal cancer liver metastases in CBA mice
J. Daruwalla (2005)



This paper is referenced by
Synthesis of a pH Responsive Polymeric Drug Delivery – tailoring functionalization for effective delivery
X. Li (2015)
10.1111/cas.12152
The link between infection and cancer: Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect
H. Maeda (2013)
Spectral molecular imaging - a new modality
N. Anderson (2013)
10.1002/cam4.109
Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
T. Fifis (2013)
Development and evaluation of nanoparticles for cancer treatment
R. O. Oliveira (2014)
10.1016/j.ijpharm.2011.08.011
Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.
N. Larson (2011)
10.1177/0883911514528144
Immuno- and hemocompatibility of amino acid pairing peptides for potential use in anticancer drug delivery
S. Naahidi (2014)
Folic Acid Conjugated Polymer as a New Active Tumor Targeting Drug Delivery Platform
X. Li (2016)
10.4155/tde.14.69
Polymeric nano-micelles: versatile platform for targeted delivery in cancer.
Salma Y. Mohamed (2014)
10.1039/C5PY00655D
Amphiphilic core cross-linked star polymers as water-soluble, biocompatible and biodegradable unimolecular carriers for hydrophobic drugs
Dunyin Gu (2015)
10.1111/micc.12228
A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next‐Generation Chemotherapeutics and Photodynamic Therapy—Problems, Solutions, and Prospects
H. Maeda (2016)
Self/Co-Assembling Peptide-based Nanocarriers for Anticancer Drug Delivery
Parisa Sadatmousavi (2014)
10.1111/cas.12592
Synthesis and therapeutic effect of styrene–maleic acid copolymer-conjugated pirarubicin
Kenji Tsukigawa (2015)
10.1007/s11523-015-0379-4
HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases
Haruhiko Dozono (2015)
10.3390/ijms141223315
Self/Co-Assembling Peptide, EAR8-II, as a Potential Carrier for a Hydrophobic Anticancer Drug Pirarubicin (THP)—Characterization and in-Vitro Delivery
Parisa Sadatmousavi (2013)
10.4172/2157-2518.S8-006
Tumor Plasticity Driven by Spatial Micro-heterogeneity in the Tumor Microenvironment Contributes to Therapy Resistance
T. Fifis (2014)
10.1021/mp400303w
Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin.
J. Zhou (2013)
10.1186/s40169-018-0185-6
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
H. Maeda (2018)
10.1016/j.biopha.2019.108764
Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis.
Y. Hong (2019)
10.1002/jbm.a.34850
Multifunctional nanomicellar systems for delivering anticancer drugs.
Y. Chen (2014)
10.1039/C1SM06378B
Dissipative particle dynamics study on the mesostructures of n-octadecane/water emulsion with alternating styrene–maleic acid copolymers as emulsifier
Shu-le Lin (2012)
10.2147/IJN.S87681
Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery – dual uptake through enterocytes and M-cells
N. Parayath (2015)
10.1016/j.xphs.2016.02.025
pH-Responsive Polymer Conjugate of Pirarubicin With Styrene Maleic Acid Copolymer as a Potential Therapeutic for Ovarian Cancer.
L. Liu (2016)
10.1002/jps.23341
In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
Aifeng Zou (2013)
10.1042/BST20180139
Membrane protein nanoparticles: the shape of things to come
K. Simon (2018)
10.1016/j.pharma.2014.04.006
Nanomedicine and its applications to the treatment of prostate cancer.
R. Ouvinha de Oliveira (2014)
10.1016/j.jconrel.2012.04.038
Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.
H. Maeda (2012)
10.4155/tde.14.36
Research spotlight: emergence of EPR effect theory and development of clinical applications for cancer therapy.
H. Maeda (2014)
10.1002/9783527634057.CH3
Enhanced Permeability and Retention Effect in Relation to Tumor Targeting
H. Maeda (2011)
Biocompatibility Evaluation of Engineered Amino Acid Pairing Peptides for Drug Delivery
Sheva Naahidi (2014)
10.1002/cmmi.1550
Clinical applications of spectral molecular imaging: potential and challenges.
N. Anderson (2014)
10.1016/J.NANTOD.2016.06.006
Nanomedicine and tumor heterogeneity: Concept and complex reality
Sandra N. Ekdawi (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar